Pfizer Price to Sales Ratio 2010-2025 | PFE
Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of May 12, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Pfizer P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2025-05-12 |
23.09 |
|
2.11 |
| 2025-03-31 |
24.87 |
$10.95 |
2.27 |
| 2024-12-31 |
25.61 |
$11.16 |
2.29 |
| 2024-09-30 |
27.51 |
$10.60 |
2.60 |
| 2024-06-30 |
26.23 |
$9.89 |
2.65 |
| 2024-03-31 |
25.62 |
$9.83 |
2.61 |
| 2023-12-31 |
26.19 |
$10.45 |
2.51 |
| 2023-09-30 |
29.77 |
$12.28 |
2.42 |
| 2023-06-30 |
32.56 |
$13.85 |
2.35 |
| 2023-03-31 |
35.83 |
$16.43 |
2.18 |
| 2022-12-31 |
44.59 |
$17.66 |
2.53 |
| 2022-09-30 |
37.76 |
$17.45 |
2.16 |
| 2022-06-30 |
44.89 |
$17.69 |
2.54 |
| 2022-03-31 |
43.97 |
$16.16 |
2.72 |
| 2021-12-31 |
49.77 |
$14.27 |
3.49 |
| 2021-09-30 |
35.94 |
$12.12 |
2.97 |
| 2021-06-30 |
32.43 |
$9.75 |
3.33 |
| 2021-03-31 |
29.71 |
$8.17 |
3.63 |
| 2020-12-31 |
29.86 |
$7.41 |
4.03 |
| 2020-09-30 |
27.96 |
$5.70 |
4.90 |
| 2020-06-30 |
24.67 |
$6.12 |
4.03 |
| 2020-03-31 |
24.38 |
$6.70 |
3.64 |
| 2019-12-31 |
28.97 |
$7.19 |
4.03 |
| 2019-09-30 |
26.31 |
$7.06 |
3.73 |
| 2019-06-30 |
31.43 |
$7.03 |
4.47 |
| 2019-03-31 |
30.54 |
$6.96 |
4.39 |
| 2018-12-31 |
31.12 |
$6.81 |
4.57 |
| 2018-09-30 |
31.18 |
$8.88 |
3.51 |
| 2018-06-30 |
25.45 |
$8.83 |
2.88 |
| 2018-03-31 |
24.66 |
$8.71 |
2.83 |
| 2017-12-31 |
24.93 |
$8.68 |
2.87 |
| 2017-09-30 |
24.35 |
$8.63 |
2.82 |
| 2017-06-30 |
22.69 |
$8.57 |
2.65 |
| 2017-03-31 |
22.89 |
$8.57 |
2.67 |
| 2016-12-31 |
21.51 |
$8.56 |
2.51 |
| 2016-09-30 |
22.21 |
$8.59 |
2.59 |
| 2016-06-30 |
22.90 |
$8.41 |
2.72 |
| 2016-03-31 |
19.11 |
$8.17 |
2.34 |
| 2015-12-31 |
20.60 |
$7.81 |
2.64 |
| 2015-09-30 |
19.89 |
$7.60 |
2.62 |
| 2015-06-30 |
21.07 |
$7.60 |
2.77 |
| 2015-03-31 |
21.68 |
$7.68 |
2.82 |
| 2014-12-31 |
19.24 |
$7.71 |
2.50 |
| 2014-09-30 |
18.11 |
$7.63 |
2.37 |
| 2014-06-30 |
18.02 |
$7.60 |
2.37 |
| 2014-03-31 |
19.33 |
$7.44 |
2.60 |
| 2013-12-31 |
18.28 |
$7.40 |
2.47 |
| 2013-09-30 |
17.01 |
$7.14 |
2.38 |
| 2013-06-30 |
16.45 |
$6.97 |
2.36 |
| 2013-03-31 |
16.81 |
$7.00 |
2.40 |
| 2012-12-31 |
14.48 |
$7.25 |
2.00 |
| 2012-09-30 |
14.22 |
$6.99 |
2.03 |
| 2012-06-30 |
13.04 |
$7.39 |
1.76 |
| 2012-03-31 |
12.72 |
$7.62 |
1.67 |
| 2011-12-31 |
12.03 |
$7.71 |
1.56 |
| 2011-09-30 |
9.73 |
$8.17 |
1.19 |
| 2011-06-30 |
11.21 |
$8.03 |
1.40 |
| 2011-03-31 |
10.95 |
$8.08 |
1.36 |
| 2010-12-31 |
9.34 |
$8.07 |
1.16 |
| 2010-09-30 |
9.07 |
$8.40 |
1.08 |
| 2010-06-30 |
7.45 |
$8.13 |
0.92 |
| 2010-03-31 |
8.86 |
$7.63 |
1.16 |
| 2009-12-31 |
9.31 |
$7.20 |
1.29 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$126.670B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
